Equities

Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)8.64
  • Today's Change0.94 / 12.21%
  • Shares traded25.33m
  • 1 Year change+613.32%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in AUD

The 3 analysts offering 12 month price targets for Clarity Pharmaceuticals Ltd have a median target of 8.48, with a high estimate of 10.00 and a low estimate of 8.20. The median estimate represents a -1.85% decrease from the last price of 8.64.
High15.7%10.00
Med-1.9%8.48
Low-5.1%8.20

Earnings history & estimates in AUD

Clarity Pharmaceuticals Ltd reported annual 2024 losses of -0.155 per share on Aug 22, 2024.
Average growth rate-31.06%
More ▼

Revenue history & estimates in AUD

Clarity Pharmaceuticals Ltd had revenues for the full year 2024 of 14.28m. This was 22.40% above the prior year's results.
Average growth rate+50.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.